605199.SH
ST葫芦娃
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 5.77
−1.70%Year over year
Reported trailing growth
- Revenue
- -44.5%
- EBITDA
- —
- EBIT
- -14.3%
- EPS
- -28.4%
- Free cash flow
- +254.8%
- Operating cash flow
- +619.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -15.9%
- EBITDA
- +15.7%
- EBIT
- +2.6%
- Net income
- -4.7%
- EPS
- -4.3%
- Free cash flow
- +117.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026